Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04019080

Enrollment

400

Registered

2019-07-15

Start date

2019-01-01

Completion date

2021-12-31

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

The objective of the current research project is, by using high quality Swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients. Secondary study objectives are to determine the clinical profile, determinants of treatment adherence, long-term safety and to describe the patient journey from the first sign of disease to end of treatment.

Interventions

OTHERAnti-fibrostic drugs

The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All subjects included in the Swedish IPF-registry

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Anti-fibrotic drugs among the patients recorded in the Swedish IPF-registry	2014-2020	The use of anti-fibrostic drugs

Countries

Sweden

Contacts

Primary ContactCarlson, RN

lisa.carlson@sll.se+46737121597

Backup ContactSköld, Prof

magnus.skold@ki.se

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026